Optimization of Therapeutic Human Serum Albumin Infusion in Selected Critically Ill Patients (AlbAlsace)
Shock, Systemic Inflammatory Response Syndrome (SIRS), Hypoalbuminaemia
About this trial
This is an interventional treatment trial for Shock focused on measuring acute circulatory failure requiring norepinephrine, SIRS, Albumin, therapeutic
Eligibility Criteria
Inclusion Criteria:
- circulatory failure requiring norepinephrine support (any dose)
- hospitalization within an Intensive Care Unit
- SIRS
- low plasma albumin (< 20g/L)
- consent to study
Exclusion Criteria:
- absence of circulatory failure
- absence of SIRS
- chronic low albumin concentration
- absence of consent to study
- inability to tolerate human serum albumin
- Patients under guardianship or curators
- Women pregnant
Sites / Locations
- Hôpitaux Universitaire de Strasbourg
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Continuous low dosage (CLD)
Intermittent high dosage (IHD)
The subjects will received human serum albumin infusion 4%.CLD patients are infused with15ml/kg/day of 4% human serum albumin from inclusion to the day norepinephrine infusion is weaned by 30% (provided their plasma albumin stays in the range 30+3g/L)
The subjects will received human serum albumin infusion 20%.IHD patients are infused with 20% human serum albumin (up to 600 ml/day) until the plasma albumin concentration is in the range 30+3g/L from inclusion to the day norepinephrine infusion is weaned by 30%